NASDAQ:INVA Innoviva (INVA) Stock Price, News & Analysis → The Key to this $10 Trillion Tech Boom (From Porter & Company) (Ad) Free INVA Stock Alerts $15.84 -0.15 (-0.94%) (As of 10:46 AM ET) Add Compare Share Share Today's Range$15.83▼$15.9550-Day Range$14.40▼$16.3752-Week Range$12.22▼$16.86Volume21,298 shsAverage Volume615,337 shsMarket Capitalization$989.05 millionP/E Ratio7.14Dividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Innoviva alerts: Email Address Ad Porter & CompanyThe Key to this $10 Trillion Tech BoomPresident Biden has just approved $2.6 billion for this breakthrough technology… And it has nothing to do with artificial intelligence, cryptocurrency, or the blockchain.To get all the details of this new tech – click here now. About Innoviva Stock (NASDAQ:INVA)Innoviva, Inc. engages in the development and commercialization of pharmaceutical products in the United States and internationally. The company's products include RELVAR/BREO ELLIPTA, a once-daily combination medicine consisting of a LABA, vilanterol (VI), an inhaled corticosteroid (ICS), and fluticasone furoate; ANORO ELLIPTA, a once-daily medicine combining a long-acting muscarinic antagonist (LAMA) and umeclidinium bromide (UMEC) with a LABA, VI; GIAPREZA (angiotensin II), a vasoconstrictor to increase blood pressure in adults with septic or other distributive shock; XERAVA (eravacycline) for the treatment of complicated intra-abdominal infections in adults; and XACDURO, a beta lactamase inhibitor for the treatment of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Its development pipeline includes zoliflodacin, a late-stage product candidate, a potential single oral dose cure for the treatment of uncomplicated gonorrhea. Innoviva, Inc. has a strategic partnership with Sarissa Capital Management LP. It has long-acting beta2 agonist (LABA) collaboration agreement with Glaxo Group Limited to develop and commercialize once-daily products for the treatment of chronic obstructive pulmonary disease and asthma. The company was formerly known as Theravance, Inc. and changed its name to Innoviva, Inc. in January 2016. Innoviva, Inc. was incorporated in 1996 and is headquartered in Burlingame, California.Read More INVA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart INVA Stock News HeadlinesJune 3, 2024 | businesswire.comInnoviva to Participate in the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 10, 2024 | finance.yahoo.comInnoviva Inc (INVA) Reports First Quarter 2024 Earnings: A Detailed AnalysisMay 10, 2024 | finance.yahoo.comInnoviva First Quarter 2024 Earnings: EPS: US$0.58 (vs US$0.51 in 1Q 2023)May 8, 2024 | investorplace.comINVA Stock Earnings: Innoviva Beats EPS, Beats Revenue for Q1 2024May 8, 2024 | businesswire.comInnoviva to Participate in the BofA Securities Health Care ConferenceApril 24, 2024 | finance.yahoo.comInnoviva Specialty Therapeutics’ Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024April 24, 2024 | businesswire.comInnoviva Specialty Therapeutics' Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024April 22, 2024 | finance.yahoo.comShould Weakness in Innoviva, Inc.'s (NASDAQ:INVA) Stock Be Seen As A Sign That Market Will Correct The Share Price Given Decent Financials?March 8, 2024 | benzinga.comInsider Decision Unfolding At Innoviva: Pavel Raifeld Exercises OptionsMarch 4, 2024 | msn.comArmata enters $35M credit agreement with InnovivaFebruary 29, 2024 | finance.yahoo.comInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressFebruary 29, 2024 | businesswire.comInnoviva Reports Fourth Quarter and Full Year 2023 Financial Results; Highlights Recent Company ProgressFebruary 28, 2024 | msn.com10 stocks you can bet on being inflation-proofFebruary 14, 2024 | finance.yahoo.comJim Simons Bolsters Position in Innoviva Inc with Recent AcquisitionFebruary 8, 2024 | morningstar.comInnoviva Inc INVAFebruary 6, 2024 | morningstar.comCosmo Pharmaceuticals NV COPNJanuary 25, 2024 | stocknews.com3 Lucrative Biotech Stock Buys for SuccessJanuary 8, 2024 | msn.comChart of the Day: Innoviva - Individual Investor FavoriteDecember 30, 2023 | finance.yahoo.comInnoviva's (NASDAQ:INVA) investors will be pleased with their 29% return over the last three yearsDecember 21, 2023 | uk.finance.yahoo.comInnoviva, Inc. (INVA) stock historical prices & data – Yahoo FinanceDecember 11, 2023 | stocknews.comAnalyzing the Bullish Opportunities of 3 Biotech StocksNovember 27, 2023 | msn.comInnoviva (INVA) Price Target Increased by 7.14% to 15.30November 18, 2023 | finance.yahoo.comInsider Sell Alert: Marianne Zhen Offloads Shares of Innoviva IncNovember 14, 2023 | finance.yahoo.comInnoviva, Inc. (NASDAQ:INVA) Has Fared Decently But Fundamentals Look Uncertain: What Lies Ahead For The Stock?November 3, 2023 | finance.yahoo.comInnoviva Inc (INVA) Reports Q3 2023 Financial Results: Net Income Drops to $82.0 MillionSee More Headlines Receive INVA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Innoviva and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/08/2024Today6/13/2024Next Earnings (Estimated)8/07/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryBiotechnology Current SymbolNASDAQ:INVA Previous SymbolNASDAQ:THRX CUSIP88338T10 CIK1080014 Webwww.inva.com Phone(650) 238-9600Fax650-827-8690Employees112Year Founded1996Profitability EPS (Most Recent Fiscal Year)$2.22 Trailing P/E Ratio7.20 Forward P/E RatioN/A P/E GrowthN/ANet Income$179.72 million Net Margins58.21% Pretax Margin63.57% Return on Equity28.94% Return on Assets15.39% Debt Debt-to-Equity Ratio0.63 Current Ratio10.42 Quick Ratio9.17 Sales & Book Value Annual Sales$311.59 million Price / Sales3.20 Cash Flow$3.51 per share Price / Cash Flow4.56 Book Value$10.66 per share Price / Book1.50Miscellaneous Outstanding Shares62,445,000Free Float61,571,000Market Cap$998.50 million OptionableOptionable Beta0.58 Social Links 20 High-Yield Dividend Stocks that Could Ruin Your RetirementAlmost everyone loves strong dividend-paying stocks, but high yields can signal danger. Discover 20 high-yield dividend stocks paying an unsustainably large percentage of their earnings. Enter your email to get this report and avoid a high-yield dividend trap.Get This Free Report Key ExecutivesMr. Pavel Raifeld C.F.A. (Age 40)Chief Executive Officer Comp: $754.67kMs. Marianne Zhen CPA (Age 55)Chief Accounting Officer & Secretary Comp: $530.21kMr. Stephen Basso M.B.A. (Age 58)Chief Financial Officer Key CompetitorsArcutis BiotherapeuticsNASDAQ:ARQTOcular TherapeutixNASDAQ:OCULKiniksa PharmaceuticalsNASDAQ:KNSAPhathom PharmaceuticalsNASDAQ:PHATSupernus PharmaceuticalsNASDAQ:SUPNView All CompetitorsInstitutional OwnershipBoston PartnersBought 185,784 shares on 5/28/2024Ownership: 0.627%Comerica BankSold 77,407 shares on 5/17/2024Ownership: 0.291%Redwood Investment Management LLCBought 12,911 shares on 5/16/2024Ownership: 0.338%California State Teachers Retirement SystemSold 5,218 shares on 5/16/2024Ownership: 0.091%Virtus Investment Advisers Inc.Sold 14,000 shares on 5/16/2024Ownership: 0.029%View All Institutional Transactions INVA Stock Analysis - Frequently Asked Questions How have INVA shares performed in 2024? Innoviva's stock was trading at $16.04 at the beginning of 2024. Since then, INVA shares have decreased by 1.1% and is now trading at $15.87. View the best growth stocks for 2024 here. When is Innoviva's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, August 7th 2024. View our INVA earnings forecast. How were Innoviva's earnings last quarter? Innoviva, Inc. (NASDAQ:INVA) announced its quarterly earnings results on Wednesday, May, 8th. The biotechnology company reported $0.46 earnings per share (EPS) for the quarter. The biotechnology company had revenue of $77.50 million for the quarter. Innoviva had a net margin of 58.21% and a trailing twelve-month return on equity of 28.94%. What ETFs hold Innoviva's stock? ETFs with the largest weight of Innoviva (NASDAQ:INVA) stock in their portfolio include LeaderShares Activist Leaders ETF (ACTV), Invesco Pharmaceuticals ETF (PJP), Harbor Health Care ETF (MEDI), ETC 6 Meridian Small Cap Equity ETF (SIXS), Pacer US Small Cap Cash Cows Growth Leaders ETF (CAFG), Conductor Global Equity Value ETF (CGV), SPDR S&P Pharmaceuticals ETF (XPH) and Roundhill Acquirers Deep Value ETF (DEEP). What other stocks do shareholders of Innoviva own? Based on aggregate information from My MarketBeat watchlists, some companies that other Innoviva investors own include Inovio Pharmaceuticals (INO), Gilead Sciences (GILD), Exelixis (EXEL), Micron Technology (MU), Advanced Micro Devices (AMD), Pfizer (PFE), Vertex Pharmaceuticals (VRTX), NVIDIA (NVDA), OPKO Health (OPK) and Sorrento Therapeutics (SRNE). Who are Innoviva's major shareholders? Innoviva's stock is owned by a variety of retail and institutional investors. Top institutional investors include Vanguard Group Inc. (9.94%), Westfield Capital Management Co. LP (3.34%), Boston Partners (0.63%), Denali Advisors LLC (0.52%), Principal Financial Group Inc. (0.51%) and Hillsdale Investment Management Inc. (0.50%). Insiders that own company stock include Alexander J Denner, Innoviva, Inc, Marianne Zhen and Pavel Raifeld. View institutional ownership trends. How do I buy shares of Innoviva? Shares of INVA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:INVA) was last updated on 6/14/2024 by MarketBeat.com Staff From Our PartnersMoonshot Coins for the Current Crypto RunAre you monitoring 13,217 cryptocurrencies everyday? If not, you could miss the ONE that can make you wealt...Crypto 101 Media | SponsoredExecutive Order To Wipe Out Your Bank AccountsDon't wait until it's too late. The digital dollar is nearing the end of its trial period, and the window of o...Oasis Gold | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredCollect 10%+ Dividends from AI's Explosive Growth?What if I told you there was a way to collect double-digit income from the AI revolution... Without having ...The Oxford Club | SponsoredBiden’s Tax Plan Could Destroy Your Retirement Savings!Leading economists are issuing stark warnings: The anticipated capital gains tax increase under President B...GoldenCrest Metals | SponsoredEstee Lauder, MAC, and other beauty brands are raving about this emerging NYSE AI companyA Little-known NYSE Company is Empowering the Beauty Industry with Innovative AI and AR Tools.Financial Markets Daily | SponsoredGold Set to EXPLODE!The perfect storm is brewing to drive gold's price through the roof! And our weakening dollars are causing ...Gold Safe Exchange | SponsoredTop 5 Tech Stocks to Buy for 2024The next evolution of technology is already upending industries worth $7 Trillion… It's already got the world'...Daily Market Alerts | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Innoviva, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Innoviva With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.